The biology underlying the concern is well understood. cTTP is caused by inherited deficiency of ADAMTS13, the enzyme that cleaves von Willebrand factor, an adhesive protein central to blood clotting. Without sufficient ADAMTS13 activity, ultra-large von Willebrand factor multimers accumulate in the circulation and sweep platelets into spontaneous microthrombi that lodge in the smallest blood vessels. Autopsy studies have found these platelet-rich clots in nearly every organ, with the brain, heart, kidneys, and digestive tract most heavily affected. Persistently low enzyme activity therefore translates into a slow, cumulative assault on the microvasculature, raising the risk of stroke, myocardial infarction, chronic kidney disease, and ultimately increased mortality, even in patients who never experience a full-blown acute TTP crisis.

Historically, the mainstay of treatment has been plasma-based therapy, in which patients receive infusions of fresh-frozen plasma, solvent or detergent-treated plasma, or plasma-derived factor VIII and von Willebrand factor concentrates that happen to carry functional ADAMTS13. These approaches help, but they are imperfect replacements. Phase 3 trial data show that plasma-based therapy restores mean peak ADAMTS13 activity to only about 19 percent of normal levels, leaving a persistent enzymatic deficit. The treatment burden is also considerable, requiring frequent hospital visits and carrying risks of severe allergic reactions and pathogen transmission. Observational cohorts reflect the consequences: a European and US study of 78 patients found organ damage in 28 percent, most often neurological, renal, and cardiac, while a Japanese cohort of 55 patients reported long-term damage in 29 percent, including renal impairment and cerebral infarction.

Recombinant ADAMTS13, developed as TAK-755 and marketed as Adzynma, changes the equation. As a laboratory-produced version of the missing enzyme, it achieves peak ADAMTS13 activity of roughly 100 percent of normal, a dramatic improvement over the partial restoration offered by plasma infusions. In a phase 3 trial of 48 patients, no acute or subacute TTP events were reported over 12 months of prophylaxis. On the strength of these data, regulators in the United States, the European Union, Japan, and the United Kingdom have approved the therapy, and the 2025 focused update of the International Society on Thrombosis and Haemostasis guidelines now recommends prophylactic recombinant ADAMTS13 over plasma-based therapy to prevent acute episodes in patients in remission. What remained unknown, however, was whether the therapy also protects against the slow accumulation of organ damage over decades.

To address that gap, the research team, led by Amie Padhiar and colleagues, followed the York protocol for structured expert elicitation, developed at the University of York as part of the STEER resources for healthcare decision making. Six UK consultant hematologists, each with at least three years of experience treating cTTP patients and direct experience managing at least one patient on prophylaxis, agreed to participate. That small number is a reflection of the disease itself: cTTP is ultra-rare, and the six clinicians who took part represent the majority of UK specialists with hands-on experience of the condition. Before making any estimates, the experts completed training on subjective probability and common cognitive biases, and received an evidence brief summarizing the phase 3 and 3b recombinant ADAMTS13 trials alongside benchmark data on plasma-based therapy.

The quantities the experts were asked to judge were carefully anchored to real trial populations. For children and adolescents, whose mean age at trial completion was 9.1 years, the panel estimated the cumulative probability of experiencing at least one long-term organ damage event, defined as stroke or transient ischemic attack, myocardial infarction, or chronic kidney disease, by ages 15, 20, and 25 years, corresponding to roughly 6, 11, and 16 years of continued prophylaxis. For adults, whose mean starting age was 38.3 years, the corresponding time points were ages 45 and 55 years. Each expert used the bisection method to identify a median, quartiles, and plausible limits for each quantity, and the individual probability distributions were then combined through unweighted linear opinion pooling using the Sheffield Elicitation Framework tool.

The aggregated projections were striking. For children and adolescents on recombinant ADAMTS13 prophylaxis, the median estimated cumulative risk of organ damage was 3.25 percent by age 15 years, rising to 4.48 percent by age 20 and 5.76 percent by age 25. For adults, the median projected risk was 4.85 percent by age 45 and 7.42 percent by age 55. When set against benchmark estimates derived from regression analysis of a retrospective study by Borogovac and colleagues, in which patients predominantly received on-demand plasma-based treatment, the contrast is substantial: the plasma-based benchmarks stood at 10.3, 17.3, and 24.4 percent at ages 15, 20, and 25 for younger patients, and at 11.4 and 25.5 percent at ages 45 and 55 for adults. Across every age point examined, the expert-elicited risks under recombinant prophylaxis were markedly lower.

The qualitative commentary from the panel helps explain why. Experts consistently attributed the lower projected risk to the higher plasma ADAMTS13 levels achieved with the recombinant therapy, combined with consistent prophylactic coverage rather than reactive, on-demand treatment. They emphasized the importance of early and regular prophylaxis, noting that children tend to be monitored more intensively than adults and that starting therapy in childhood may prevent subclinical damage that would otherwise accumulate before diagnosis. Several experts suggested the benefits of recombinant ADAMTS13 would become more apparent with longer follow-up, particularly for vascular health. Adherence emerged as a critical variable: one expert warned that missed doses could account for residual cases of end-organ damage, and the adolescent-to-adult transition was flagged as a particularly vulnerable period requiring structured adherence support. By age 55, uncertainty widened, reflecting comorbidities, smoking, and the possible late manifestation of subclinical damage sustained earlier in life.

The authors and independent observers alike stress that these numbers are projections, not observations. The credible intervals around the estimates are wide, particularly at older ages, spanning for example from under 1 percent to nearly 30 percent for adults by age 55, and the distributions were consistently right-skewed, with most experts predicting low risks but a few anticipating higher ones. The benchmark comparison is contextual rather than a head-to-head trial, since the Borogovac cohort largely received on-demand therapy that does not reflect current UK practice, and no causal claims about comparative effectiveness can be drawn. The composite endpoint also obscures potential differences between neurological, cardiac, and renal risks. Funding came from Takeda, the therapy’s manufacturer, and several authors are company employees or consultants, factors the paper discloses transparently.

Nevertheless, the study fills a genuine void. For ultra-rare diseases where decades-long prospective trials are logistically impossible, structured expert elicitation offers a transparent, bias-mitigated way to generate the kinds of risk estimates that clinicians, patients, and health technology assessment bodies need today. The findings suggest that sustained recombinant ADAMTS13 prophylaxis may substantially reduce the lifetime burden of organ damage in cTTP, reinforcing the value of early initiation and unwavering adherence. They also chart the path forward: prospective registries with long-term follow-up, organ-specific risk modeling, and validation of these projections against real-world outcomes. Until such data arrive, these expert-derived estimates stand as the best available evidence, and they paint a picture in which a once-devastating inherited disorder may increasingly be managed as a chronic condition with a far gentler long-term trajectory.

Subject of Research: Projected long-term organ damage risk in congenital thrombotic thrombocytopenic purpura patients treated with recombinant ADAMTS13 prophylaxis, estimated through structured expert elicitation

Article Title: Estimating Long-Term Organ Damage Risk in Patients with Congenital Thrombotic Thrombocytopenic Purpura Receiving Recombinant ADAMTS13 Prophylaxis: A Structured Expert Elicitation Study

Article References: Padhiar, A., Burke, C., Puls, M., Berkley, A., Heard, O., Kaur, H., Wolff, H., & Murphy, L. (2026). Estimating Long-Term Organ Damage Risk in Patients with Congenital Thrombotic Thrombocytopenic Purpura Receiving Recombinant ADAMTS13 Prophylaxis: A Structured Expert Elicitation Study. Advances in Therapy. https://doi.org/10.1007/s12325-026-03786-y

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03786-y

Keywords: congenital thrombotic thrombocytopenic purpura, recombinant ADAMTS13, structured expert elicitation, organ damage, plasma-based therapy, von Willebrand factor, stroke, chronic kidney disease, myocardial infarction, prophylaxis, rare disease, health technology assessment

Hemophilia is an inherited bleeding disorder caused by deficiencies in clotting factor VIII, in the case of hemophilia A, or factor IX, in the case of hemophilia B. Because these proteins are essential for forming stable blood clots, affected individuals bleed for longer than normal after injury and can bleed spontaneously into joints, muscles, and, most dangerously, the brain. The disorder is passed on through the X chromosome, so it overwhelmingly affects boys, while girls are typically carriers. What makes the neonatal period so treacherous is the combination of an immature coagulation system, the mechanical stresses of labor and delivery, and the fact that many affected infants are born into families with no known history of the disease. In roughly a third of cases, hemophilia appears in a child with no prior family history, arising from a new genetic mutation, which means neither obstetricians nor parents may anticipate the bleeding risk before delivery.

Intracranial hemorrhage in a newborn is a medical emergency of the highest order. Bleeding can occur in several compartments of the skull: inside the brain tissue itself, in the subdural space beneath the dura mater, in the subarachnoid space surrounding the brain, or within the ventricles, the fluid-filled cavities deep in the brain. In a baby with hemophilia, even a minor trauma during delivery, such as the pressure of forceps, a vacuum extraction, or a prolonged second stage of labor, can trigger bleeding that a healthy infant’s clotting system would quickly contain. Symptoms may include seizures, lethargy, vomiting, a bulging fontanelle, pallor, or simply poor feeding and irritability, and because these signs overlap with many other neonatal conditions, diagnosis is often delayed. Untreated, the bleed can expand, compressing brain tissue and causing permanent damage or death.

The true scale of the problem has long been difficult to pin down. Previous estimates of neonatal ICH risk in hemophilia have ranged widely across the literature, from figures below one percent to reports suggesting rates several times higher. The authors of the new analysis attribute this fragmentation to heterogeneous study designs, small single-center cohorts, differing diagnostic criteria, and inconsistent surveillance practices. Some studies relied on clinical symptoms alone, others on routine cranial imaging, and the era in which each study was conducted matters as well, since the availability of neonatal ultrasound, computed tomography, and magnetic resonance imaging has changed dramatically over recent decades. By systematically searching PubMed, Embase, and Scopus from their inception through November 2025 and applying consistent eligibility criteria, requiring reported ICH within the first twenty-eight days of life among live-born neonates with hemophilia, the team sought to produce the most reliable estimate to date.

The statistical machinery behind the study is standard for modern evidence synthesis but worth unpacking. Rather than simply averaging the results of the thirteen included studies, the researchers used a random-effects meta-analysis, a model that assumes each study estimates its own true incidence and that these true values are distributed around a common mean. This approach is appropriate when between-study heterogeneity is high, which the authors confirmed it was. Heterogeneity in this context means the studies differed substantially in their reported rates, likely reflecting differences in geography, era, severity of hemophilia represented, mode of delivery, and intensity of diagnostic workup. The random-effects model widens the confidence interval to account for this variability, which is why the pooled estimate of 2.10 percent carries an interval stretching from 1.40 to 2.79 percent rather than a razor-thin range.

One of the more sobering findings concerns mortality. The pooled estimate for fatal neonatal ICH was approximately 0.2 percent, with a 95 percent confidence interval of 0.0 to 1.2 percent. In other words, among every thousand live-born neonates with hemophilia, roughly two may die from a brain bleed in the first month of life, though the wide interval reflects the rarity of the event and the limits of the available data. Fatal bleeds were rare in absolute terms, but the analysis underscores that when ICH does occur, it carries the potential for catastrophic outcomes. Survivors of neonatal ICH can face cerebral palsy, epilepsy, developmental delay, and cognitive impairment, making prevention far more valuable than even the best acute treatment.

Prevention, the authors argue, hinges on three pillars: early diagnosis, careful perinatal management, and avoidance of traumatic delivery techniques. Early diagnosis means identifying at-risk infants before or immediately after birth, ideally through known family history, carrier testing, or, in some health systems, targeted newborn screening of male infants born to carrier mothers. Careful perinatal management involves coordinating obstetric and hematology teams well before delivery, planning the mode of birth to minimize trauma, and avoiding invasive monitoring such as fetal scalp electrodes or vacuum and rotational forceps deliveries when a baby is known or suspected to have hemophilia. For infants diagnosed after birth, prompt replacement of the missing clotting factor can halt bleeding before it spreads, and some guidelines recommend prophylactic factor replacement for high-risk neonates during the vulnerable first days of life.

The study’s findings arrive amid a broader shift in hemophilia care. Prophylactic clotting factor infusions, once reserved for older children with severe disease, are increasingly considered earlier, and newer agents, including extended half-life factor products and bispecific antibodies that mimic factor VIII activity, have transformed long-term management. Yet the neonatal window remains a blind spot in many treatment pathways, because diagnosis itself may lag behind the highest-risk period. The authors call for dedicated neonatal-focused registries and prospective studies to refine risk stratification, arguing that only systematically collected, individual-level data can identify which babies are most likely to bleed and which preventive strategies work best. Such registries could track delivery mode, factor levels at birth, family history, imaging findings, and outcomes in a standardized way across centers and countries.

The meta-analysis also highlights persistent gaps in the evidence base. The thirteen included studies spanned different decades, healthcare settings, and diagnostic standards, and the authors note that the substantial heterogeneity between them limits the precision of any single pooled estimate. Retrospective designs dominated, and few studies distinguished between severity categories of hemophilia, modes of delivery, or the timing and type of diagnostic imaging. Without prospective, standardized surveillance, some bleeds may go undetected, particularly small hemorrhages that produce subtle or absent symptoms in the first days of life. This means the true incidence could, in principle, be higher than the pooled estimate suggests, a possibility the authors acknowledge indirectly through their call for better data.

For clinicians and families, the practical message is clear. A 2.10 percent risk is low enough that most newborns with hemophilia will never experience a brain bleed, but high enough that every birth should be treated as an opportunity for prevention. When hemophilia is known or suspected before delivery, obstetric teams can choose the least traumatic route of birth, neonatologists can maintain a low threshold for cranial imaging, and hematologists can have replacement factor ready at the bedside. When there is no family history, the challenge is harder, but the growing availability of genetic carrier screening and heightened awareness among providers can shorten the path from first symptom to diagnosis and treatment. The study, published open access on October 6, 2026, and citable under DOI 10.1186/s12887-026-07750-1, adds a carefully quantified data point to a field that has long operated on fragmented numbers, and it makes a compelling case that the first twenty-eight days of life deserve far more systematic attention in the care of children with hemophilia.

Subject of Research: Neonatal intracranial hemorrhage risk in infants with hemophilia

Article Title: Risk of intracranial hemorrhage in neonates with hemophilia: a systematic review and meta-analysis

Article References: Zheng, M., Zheng, H., Li, Y., & Tu, J. (2026). Risk of intracranial hemorrhage in neonates with hemophilia: a systematic review and meta-analysis. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07750-1

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07750-1

Keywords: hemophilia, intracranial hemorrhage, neonatology, meta-analysis, systematic review, clotting factors, bleeding disorders, perinatal care, newborn screening, prophylaxis, BMC Pediatrics, birth trauma

The central problem the work addresses is a familiar one in phage therapy: lytic phages are remarkably effective at killing their bacterial targets in a dish, but their performance in the gut often falls short of expectations. The mammalian intestine is a crowded, chemically complex environment in which introduced phages can be diluted by gut transit, inactivated by changes in pH and bile, adsorbed by mucus and particulate matter, or simply outcompeted by the sheer density of resident microbes. Concentrations of phage that would rapidly clear a bacterial culture in vitro may never reach the threshold needed to suppress a pathogen in vivo, particularly when treatment begins before an infection has taken hold.

Prophylactic phage therapy—giving phages in advance of exposure to a pathogen—makes this problem especially acute. If phages are administered orally as free virus particles, they must survive passage through the stomach, persist in the intestinal lumen for an extended period, and remain at effective concentrations until the pathogen arrives. Because lytic phages only replicate when they encounter susceptible host bacteria, a prophylactically delivered phage that meets no target simply decays. The new study’s answer is to stop thinking of the phage as the delivered agent and start thinking of a bacterium as the delivery vehicle.

The researchers engineered bacterial strains to encode prophages in their genomes. A prophage is the integrated, dormant form of a temperate phage: its DNA is replicated along with the host cell’s chromosome and passed to daughter cells at division, effectively turning each carrier bacterium into a self-replicating archive of viral genetic material. Under normal conditions the prophage remains silent, allowing the carrier strain to colonize the gut without being lysed. When the carrier population encounters a susceptible target bacterium—or when conditions trigger prophage induction—the integrated phage can enter its lytic cycle, producing new virions that are then released directly into the intestinal environment.

This design has several consequences that make it attractive as a prophylactic strategy. First, because the phage genome is maintained by a replicating bacterial population, the viral payload is continuously renewed rather than passively decaying, which addresses the persistence problem that undermines conventional prophylactic dosing. Second, phage production occurs in situ, in the same compartment the pathogen will occupy, sidestepping the barriers that degrade or dilute phages delivered from outside. Third, the system couples phage release to the ecology of the gut itself: the carrier strain establishes, persists, and produces virions locally, creating a standing population of lytic phage that is already in position when a pathogen attempts to establish infection.

In the mouse experiments described in the paper, animals that received the prophage-encoding engineered bacteria before pathogen challenge were protected against enteric infection, with the released lytic phages suppressing the target pathogen in the intestine. The authors frame this as prophylactic lytic phage therapy achieved through a biological delivery system—combining the killing power of lytic phages with the persistence and localization of a colonizing bacterial carrier. The results, they argue, demonstrate that engineered prophage carriers can convert the gut itself into a manufacturing site for therapeutic phages.

The technical achievement rests on a set of design decisions that reflect the peculiar biology of temperate phages. A prophage must be stable enough not to spontaneously induce and destroy its own carrier population, yet inducible enough to produce virions on a useful timescale. The carrier strain must be able to colonize the mouse gut without causing harm, must not be eliminated by the resident microbiota, and must not itself become the target of the phage it carries. Immunity mechanisms—typically conferred by prophage-encoded repressors—keep the carrier protected from its own phage, while the phage’s host range determines which pathogens the released virions can attack. Balancing these constraints is the core engineering challenge, and the study’s success in mice suggests the authors found a workable equilibrium.

The work also speaks to a broader conceptual shift in phage therapy. Most clinical and preclinical phage programs treat phages as drugs: purified virus preparations, dosed and formulated like small molecules or antibodies. That paradigm has produced encouraging results in compassionate-use cases and early trials, particularly for antibiotic-resistant infections, but it inherits the pharmacological weaknesses of a self-replicating, target-dependent agent. The prophage-carrier approach instead treats the phage as part of a living system, embedded in a bacterial chassis that handles persistence, localization, and production. In this view, the therapeutic unit is not a vial of virus but an engineered member of the gut community.

That shift brings both opportunities and questions. Living carriers can be designed to respond to environmental cues, to carry multiple prophages against different pathogens, or to be genetically confined through auxotrophy or kill switches—features that are impossible with purified phage preparations. At the same time, releasing engineered organisms and their viral payloads into the gut raises ecological and regulatory questions that purified phages do not: how stably the carrier colonizes, whether the integrated prophage spreads horizontally to other bacteria, how the resident microbiota responds to chronic phage production, and how such a product would be evaluated by regulators accustomed to defined molecular drugs. The mouse data establish proof of principle; translating it will require answering these questions in more complex microbial communities and, eventually, in hosts whose guts differ substantially from those of laboratory mice.

The study also contributes to a growing literature on the natural role of prophages in gut ecology. Most bacteria in the mammalian intestine carry prophages, and induction of these elements under stress conditions is increasingly recognized as a driver of bacterial competition and microbiome dynamics. The engineered system described in Nature Microbiology essentially harnesses a natural phenomenon—prophage carriage and induction—for a therapeutic purpose, turning a widespread biological mechanism into a controllable intervention. Whether that intervention can be made safe, predictable, and generalizable remains to be seen, but the mouse results mark a concrete step toward phage therapies that are deployed not as doses but as residents.

For a field confronting the relentless spread of antibiotic resistance in enteric pathogens, the appeal of a prophylactic strategy is obvious. Preventing an intestinal infection before it establishes is easier, safer, and cheaper than treating one that has already taken hold, and phages offer a specificity that broad-spectrum antibiotics cannot match—killing the pathogen while sparing the rest of the community. By encoding that specificity in a colonizing bacterium, the new work proposes a way to keep the weapon loaded and in place until it is needed. If the approach survives the translational challenges ahead, prophage-encoding carriers could become a template for a new class of living, prophylactic antimicrobials designed to guard the gut against its most dangerous inhabitants.

Subject of Research: Engineering prophage-encoding bacteria as living carriers for prophylactic lytic phage therapy against enteric infection in mice

Article Title: Prophage-encoding engineered bacteria enable prophylactic lytic phage therapy for enteric infection in mice

Article References: Bataglioli, R. A., Baaziz, H., Avalos, H. F., Smith, L., Baker, Z. R., Makhlouf, R. J., da Silva Barreira, D., Kaur, H., Southard, T., & Hsu, B. B. (2026). Prophage-encoding engineered bacteria enable prophylactic lytic phage therapy for enteric infection in mice. Nature Microbiology. https://doi.org/10.1038/s41564-026-02484-3

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02484-3

Keywords: bacteriophage therapy, prophage, engineered bacteria, enteric infection, gut microbiome, lytic phage, prophylaxis, mouse model, antimicrobial resistance, synthetic biology, Nature Microbiology, phage delivery